A detailed history of Catalina Capital Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Catalina Capital Group, LLC holds 781 shares of VRTX stock, worth $363,227. This represents 0.14% of its overall portfolio holdings.

Number of Shares
781
Previous 693 12.7%
Holding current value
$363,227
Previous $290 Million 26.37%
% of portfolio
0.14%
Previous 0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$392.81 - $485.53 $34,567 - $42,726
88 Added 12.7%
781 $366 Million
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $282,529 - $309,133
693 New
693 $290 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Catalina Capital Group, LLC Portfolio

Follow Catalina Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalina Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalina Capital Group, LLC with notifications on news.